Vivimed Labs Ltd.
Snapshot View

22.55 -0.60 ▼-2.6%

04 August 2021, 04:00:00 P.M.
Volume: 55,908

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.vivimedlabs.com
Financial Indicators
Market Cap 186.97 Cr.
Earnings per share (EPS) -9.38 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 32.95 Trailing Twelve Months Ending 2021-03
Book Value / Share 47.47 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.48 Calculated using Price: 22.55
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 8.29 Cr. 82,913,915 Shares
FaceValue 2
Company Profile

Vivimed Labs Ltd was originally incorporated as Emgi Pharmaceuticals & Chemicals Private Limited on 22-09-1988 with Registrar of Companies of Karnataka, Bangalore and subsequently converted into a public limited company on April 21, 1994. The name of the company has been changed to Vivimed Labs Limited on  April 22,1997.

The company was originally promoted by A. M. Rao. In 1989  Santosh Varalwar and  Subhash Varalwar acquired Emgi Pharmaceuticals and Chemicals Limited and commenced manufacturing of bulk drugs in 1991.

The company’s manufacturing unit is located at Bidar, Karnataka, where it was originally engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs like Ibuprofen etc. However, due to downward price movement in the products of the company during 1995, it gradually moved over to manufacturing specialty chemicals and cosmetic ingredients like Triclosan, Avis etc. catering to global and domestic markets.

Vivimed started production of Triclosan with a very small capacity of 5 MT p.a. in the year 1999 and increased its capacity to 225 MT p.a. over a period of next 5 years. The production capacity was further doubled by adding one more production block in March 2004.

Touching lives on another front, they are fighting microbes in home. In the kitchen, in the linen and more, their antimicrobials deliver clean living. Their high-end chemistry also coats the screen of mobile telephone and car’s photochromatic windscreen. For the photographic industry they remain a timeless answer. Their photosynthetic and photographic chemicals have been products of choice for decades now.

Product range of the company includes:

  • Triclosan  VIV 20
  • Avis (Avo benzone)
  • Calcium Glycero Phosphate (CaGP)
  • Chlorphenesin – Cosvat (Anti Fungal)
  • NDGA (Anti-oxidant)
  • Hair care
  • Oral care
  • Anti microbial
  • Skin care
  • Sun care

Milestones:

1988 & 1989•  Incorporated on September 22, 1988•  Death of original promoter Mr. A. M. Rao•  Acquired by Mr. Santosh Varalwar and Mr. Subhash Varalwar

1990 •  Commenced production of Non-Steroidal Anti-Inflammatory Drug (NSAID) – IBUPROFEN.

1994 •  Diversification and expansion of product mix by adding other APIs viz. Chlorzoxazone (Skeletal disorders), Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal).

1995 •  Diversification into specialty chemicals by production of Triclosan.

1996 •  R&D was commenced with facilities having an integrated instrumentation for organicsynthesis, Microbiology and pre-formulation studies.

1997 •  Process Innovation of Anti-bacterial and clearance of innovative route of synthesis for Triclosan.• Grant of patent for VIV-20 (Triclosan) by the Indian Patents Office.1998 – 99• Qualified for supply to Unilever’s Asian locations after Audit of manufacturing facility by a team of Unilever Plc.•  Triclosan customer base expanded to UK, France, Germany as well as domestic market.

2002 •  Approved by Unilever group Companies in Asian/Middle & Far East Companies for usage of Enamel Protective Agent manufactured by the company in their oral care formulations.•  Developed Anti-fungal for usage in High-end cosmetic and pre-formulation blends.•  Vivimed emerges as a second chemical company located outside USA/Europe to get the US EPA’s registration for Triclosan as 99% ingredient.•  Vivimed’s Quality Management System gets ISO 9001:2000 certification.

2003 •  Signed Confidential Sale Agreement with HLL for R&D, scaling up and commercialization of product coded as A123.•  Commencement of EMS Audit for ISO 14001 certification.

2004 •  Introduced new products for anti-dandruff and skin care application•  Triclosan production capacity increased from 225 MT p.a. to 480 MT p.a.•  Developed novel synthetic process to manufacture a premium anti-oxidant and anti-cancer molecule branded as VINTOX

2012 • Vivimed launch Nisarg Soapnut at in-cosmetics, Barcelona.

2013• Vivimed Labs Limited signed an agreement to acquire Actavis Pharma Manufacturing Pvt. Ltd.’s solid oral dosage (“SOD”) facility in Alathur, Tamil Nadu, India. The facility acquired from its parent Actavis Holding Asia B.V., an affiliate of Actavis Inc.

2014 • Vivimed received the PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) GMP (Good Manufacturing Practice) approval for one of its pharmaceuticals manufacturing facilities in Jeedimetla, Hyderabad for the supply of finished dosage formulations to the CIS (Commonwealth of Independent States) region.

Achievements/ recognition:

  • ISO 9001:2000 and ISO14001

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.59%
1 Week
-1.31%
1 Month
-9.44%
3 Month
-26.55%
6 Month
+38.77%
1 Year
+93.56%
2 Year
+40.06%
5 Year
-69.91%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 26.70 23.34 14.81 14.90 16.50 35.18 9.76 7.95 -20.75
Return on Capital Employed (%) 14.29 13.83 11.93 10.91 11.93 21.86 9.04 7.03 -2.69
Return on Assets (%) 6.69 5.83 3.90 3.86 4.25 10.44 3.43 2.44 -4.83

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 475 509 560 559 585 734 1,226 944 835
Non Curr. Liab. 361 450 533 538 561 504 357 490 591
Curr. Liab. 464 611 744 801 897 817 790 889 770
Minority Int. 12
Equity & Liab. 1,299 1,570 1,837 1,898 2,044 2,055 2,386 2,322 2,196
Non Curr. Assets 604 736 846 906 911 961 1,104 1,092 1,221
Curr. Assets 647 815 971 992 1,133 1,094 1,282 1,231 975
Misc. Exp. not W/O 48 18 20 0 0
Total Assets 1,299 1,570 1,837 1,898 2,044 2,055 2,386 2,322 2,196

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 668 1,109 1,351 1,380 1,346 1,462 1,186 1,315 1,059
Other Income 3 26 36 8 24 8 24 34 12
Total Income 671 1,135 1,387 1,388 1,369 1,470 1,209 1,349 1,071
Total Expenditure -538 -928 -1,166 -1,158 -1,123 -1,057 -985 -1,146 -1,052
PBIDT 133 207 220 230 247 413 224 203 19
Interest -28 -50 -67 -86 -85 -68 -82 -70 -61
Depreciation -27 -59 -66 -66 -61 -58 -56 -67 -67
Taxation -15 -14 -20 -5 -16 -73 -10 -9 0
Exceptional Items
PAT 63 84 66 72 84 214 76 57 -109

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 45 90 -118 140 154 58 21 422 80
Cash Fr. Inv. -424 -170 -291 -107 -190 -68 -164 -89 -196
Cash Fr. Finan. 404 67 419 -42 41 35 186 -338 72
Net Change 25 -12 11 -8 4 25 44 -5 -44
Cash & Cash Eqvt 36 24 35 27 31 55 99 95 50

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 34.23 34.23 34.23 32.79 32.79 32.79 32.79 28.57 28.57
Public 65.77 65.77 65.77 67.21 67.21 67.21 67.21 71.43 71.43
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 66.37 66.37 66.37 63.40 60.09 60.09 60.09 54.20 54.20

Announcements View Details

Mon, 02 Aug 2021
Board Meeting Intimation for Notice Of Board Meeting / Closure Of Trading Window
VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 30.06.2021 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 13th Day of August 2021 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the quarter ended 30th June 2021.

Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.07.2021 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the quarter ended 30th June 2021.

Kindly take the above information on records.
Mon, 26 Jul 2021
Disclosure Of Related Party Transactions For The Half Year Ended 31.03.2021
Disclosure of Related Party Transactions for the Half Year Ended 31.03.2021
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Vivimed Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Tue, 03 Aug 2021
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Doji and Near Doji Doji and Near Doji
Mon, 02 Aug 2021
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
MFI Bullish MFI Bullish
Fri, 30 Jul 2021
S Close Below Last Month Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 190,711.14 785.75 -1.1%
Divi's Laboratories Ltd. 132,945.34 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. 78,541.95 4,768.80 +1.0%
Cipla Ltd. 74,795.92 939.65 +1.2%
Cadila Healthcare Ltd. 60,600.44 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. 58,835.96 4,066.40 -0.6%
Piramal Enterprises Ltd. 56,942.27 2,550.50 +1.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.77 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 67.00 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.21 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 31.10 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.40 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 391.30 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 42.74 2,550.50 +1.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.98 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 14.30 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 4.09 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.80 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.66 2,550.50 +1.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,768.80 +1.0%
Cipla Ltd. Consolidated 2020-03 0.18 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,768.80 +1.0%
Cipla Ltd. Consolidated 2020-03 10.09 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,768.80 +1.0%
Cipla Ltd. Consolidated 2020-03 12.53 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,550.50 +1.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,768.80 +1.0%
Cipla Ltd. Consolidated 2020-03 19,159.59 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,550.50 +1.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,768.80 +1.0%
Cipla Ltd. Consolidated 2020-03 2,401.30 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,550.50 +1.7%